On-Demand CME/CE

Current and Future RSV Prevention Strategies:
What Every Practitioner Needs to Know

Web Based On-Demand Activity

The Pediatric Respiratory Care Initiative^™ (PRCI^®) is pleased to present this interactive CME/CE On-Demand Activity presented by:

FACULTY

John P. DeVincenzo III, MD, Co-Chair
Associate Professor of Pediatrics and Molecular Sciences
University of Tennessee School of Medicine
Memphis, Tennessee

Jaime E. Fergie, MD
Associate Professor of Pediatrics
Texas A&M University College of Medicine
College Station, Texas

Caroline B. Hall, MD, Co-Chair
Professor of Pediatrics and Medicine
University of Rochester School of Medicine and Dentistry
Rochester, New York

Planning Committee

H. Cody Meissner, MD
Chief, Division of Pediatric Infectious Disease
Professor of Pediatrics
Tufts University School of Medicine
Boston, Massachusetts

Thuy N. Nguyen, PharmD
Assistant Professor
University of Southern California School of Pharmacy
Los Angeles, California

Concettina Tolomeo, APRN, FNP, BC, AE-C
Director, Program Development
Yale University School of Medicine
New Haven, Connecticut

Program Overview

Respiratory syncytial virus (RSV) infections are complex and may have a substantial and subsequent impact on the health of many children who are considered at high risk. Frontline healthcare professionals must recognize those at greatest risk and be cognizant of the current treatment protocols and prophylactic measures.

This activity will begin with a review of the 2006 guidelines issued by the American Academy of Pediatrics (AAP) for the management of children with bronchiolitis and the 2006 recommendations for the management of RSV. Topics such as identifying the groups indicated for prophylaxis, recognizing the clinical manifestations of RSV, and understanding how to decide if a child needs hospitalization will all be covered. Finally, an overview of the therapeutic modalities currently available, as well as those in development, will be highlighted.

The activity will feature the highlights of the Phase 3 trial comparing motavizumab with palivizumab in children given either medication. Details of the study findings, the potential implications of the study, and its impact on the treatment of RSV for pediatricians and other healthcare professionals working the clinical front lines will be discussed. Finally, the focal point of the activity will be the review of a case study that will serve as the platform to an interactive discussion with the faculty panel.

Target Audience

This educational activity is designed for pediatricians, pediatric nurse practitioners, pediatric medical subspecialties, and other healthcare professionals involved in the care and management of pediatric respiratory patients.

Learning Objectives

After participating in this activity, participants should be able to:
- Identify the current guideline recommendations, issued by the AAP, for the treatment of high-risk infants who present with RSV and for the management of children with bronchiolitis
- Identify the patients at high risk for RSV and who are eligible for appropriate prophylactic treatment
- Discuss the current status of the development of anti-RSV therapies, including the results of the Phase 3 trial comparing motavizumab with palivizumab treatments in infants at high risk for serious RSV disease

Sponsor

This educational activity is conducted as a part of the Pediatric Respiratory Care Initiative^TM (PRCI^®), sponsored by Professional Postgraduate Services^®, Secaucus, NJ.

Professional Postgraduate Services^® (PPS) is a business unit of KnowledgePoint360 Group, LLC, Secaucus, NJ.

CME/CE Credit

Professional Postgraduate Services^® designates this educational activity for a maximum of 1.75 AMA PRA Category 1 Credits^TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

This program has been approved for 1.75 contact hours of continuing education by the American Academy of Nurse Practitioners. Program ID 0801011.

This on-demand educational activity offers continuing medical education (CME), and continuing nurse practitioner contact hours. Participants who wish to receive the appropriate credit for this educational activity should do the following: (1) view the on-demand program; and (2) complete the post-test and evaluation form.

Grantor

The Pediatric Respiratory Care Initiative^TM (PRCI^®) and this educational activity are supported by an educational grant from MedImmune, Inc.

Disclosures

This educational activity is intended to provide current information on issues concerning RSV. Some of the information presented about the agents mentioned may include discussion of off-label or investigational, non-FDA-approved uses. Please refer to each manufacturer's full prescribing information before prescribing any of the agents mentioned in these activities. Please note: slides in the publication that include discussion of off-label or investigational uses are identified with the symbol .

Faculty Financial Disclosures

Faculty were asked to disclose whether they have any relevant financial relationships occurring within the past 12 months with a commercial interest:

Dr DeVincenzo indicated that he receives grant/research support and is a retained consultant for Arrow Pharmaceuticals Inc, Becton, Dickinson and Company, and MedImmune, Inc.; receives grant/research support from Alnylam Pharmaceuticals, Inc.; and is a retained consultant for Tibotec, Inc.

Dr Fergie indicated that he receives grant/research support from MedImmune, Inc.; is a member of the speakers bureau for MedImmune, Inc., Merck & Co., Inc., and sanofi pasteur; and is on the advisory board for MedImmune, Inc. and Merck & Co., Inc.

Dr Hall indicated that she receives grant/research support from and is on the advisory board for MedImmune, Inc.

Dr Meissner indicated that he receives grant/research support from MedImmune, Inc. and Wyeth Pharmaceuticals; and is a retained consultant for GlaxoSmithKline, MedImmune, Inc., and Merck & Co., Inc.

Dr Nguyen has indicated that she has no relevant financial relationships to disclose.

Ms Tolomeo has indicated that she has no relevant financial relationships to disclose.

Professional Postgraduate Services^® Staff

Grace L. McBride, Senior Managing Editor; Mark Palangio, Senior Medical Writer; Luis Pichardo, Program Manager; Wadee'ah Terry, CME Program Manager; and Megan Tierney, Program Director, have indicated that they have no relevant financial relationships.

This interactive CME/CE On-Demand Activity has been peer reviewed by CME Peer Review, LLC, which has no relevant financial relationships to disclose.

About PRCI

The Pediatric Respiratory Care Initiative^TM (PRCI^®) is a multicomponent educational program on pediatric respiratory disorders designed for pediatricians, infectious disease specialists, allergists, immunologists, primary care physicians, and other healthcare professionals involved in the care and management of pediatric respiratory patients. PRCI programs address issues concerning respiratory syncytial virus (RSV) and other respiratory tract infections and disorders. Methods to prevent, control, and treat respiratory illnesses are also evaluated.

Copyright © 2008 Professional Postgraduate Services^®. All rights reserved.

This activity may not be reproduced in whole or in part without the express written permission of Professional Postgraduate Services^®.

Pediatric Respiratory Care Initiative and PRCI are trademarks used herein under license.

Original release date: February 25, 2008
Valid through date: February 25, 2009

Method of Participation
1) Complete the CME/CE Activity
2) Complete the post-test
3) Complete the Evaluation form
4) Print or download the CME certificate

Participants who complete the activity online have the ability to download their CME credit certificate upon the completion of the program. Statement of credit for continuing nurse practitioner credit will be mailed within 6 to 8 weeks.

To view this program online, the following technology is recommended:

WINDOWS PC SYSTEM REQUIREMENTS:

266-MHz Pentium II; Windows 98; 64 MB RAM; 800 x 600 screen resolution set for "High Color (16-Bit)"; speakers; 16-Bit SoundBlaster or SoundBlaster-compatible sound card; Macromedia Flash player 6 or higher.

MACINTOSH^® SYSTEM REQUIREMENTS:

Power Mac G3 at 300 MHz; System 8.5 or higher (excluding Mac OSX); 96 MB RAM; 20 MB minimum hard disk space available; 800 x 600 screen resolution set to "Thousands of Colors"; Macromedia Flash player 6 or higher.